EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudie

Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I–III pancreatic ductal adenocarcinoma

Thaninee Prasoppokakorn iD, Roongruedee Chaiteerakij, Areeya Buntho, Praewphan Ingrungruanglert, Nipan Israsena, Wiriyaporn Rittitid, Phonthep Angsuwatcharakon iD, Parit Mekaroonkamol, Pradermchai Kongkam iD, Rungsun Rerknimitr iD

Endoscopy · 2025-08 · 57 (08) · 901-909

DOI: 10.1055/a-2535-7440 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Endoscopy, online erschienen am 27.03.2025. Verfasst von Thaninee Prasoppokakorn und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Neoplastic Cells, Circulating, Pancreatic Neoplasms, Portal Vein. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: The Second Century Fund (C2F), Chulalongkorn University, Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology annual fund, Chulalongkorn University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The detection of portal venous circulating tumor cells (CTCs) may better reflect vascular metastasis and predict micrometastasis risk than peripheral blood in patients with pancreatic ductal adenocarcinoma (PDAC). We hypothesize that portal CTCs could better represent micrometastasis and can predict survival in PDAC patients. A single-center, prospective cohort study of patients with stage I–III PDAC was conducted. Portal venous blood was obtained via endoscopic ultrasound-guided sampling, and peripheral blood was collected on the same day. CTCs were detected using EpCAM and mucin1 antibodies and reported as cells/8 mL of blood. Among 35 patients, the portal and peripheral CTC detection rates were 94.3% and 82.9%, respectively. Advanced PDAC with locoregional metastasis had higher portal CTCs than less aggressive disease (P < 0.05), while peripheral CTCs showed no significant differences. During the 50-month follow-up, patients with portal CTCs ≥8 had poorer survival (6.1 vs. 19.0 months; P = 0.001) and patients with peripheral CTCs ≥3 also had poorer survival (4.6 vs. 14.2 months; P = 0.002). In multivariable analysis, both portal CTCs ≥8 and peripheral CTCs ≥3 showed significant adjusted associations with survival (adjusted hazard ratio 3.4 [P = 0.009] and 2.7 [P = 0.02], respectively). Higher CTC counts in both the portal and peripheral systems were significantly associated with poorer survival in stage I–III PDAC; however, only portal CTCs reflected tumor aggression and locoregional metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalNeoplastic Cells, CirculatingPancreatic NeoplasmsPortal VeinAgedAged, 80 and overFemaleHumansMaleMiddle AgedBiomarkers, TumorEpithelial Cell Adhesion MoleculeNeoplasm MicrometastasisNeoplasm StagingPrognosisProspective StudiesCross-Sectional Studies

Substanzen

Biomarkers, TumorEpithelial Cell Adhesion Molecule

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Faculty of Medicine, Chuallongkorn University, Bangkok, Thailand.
  • Center of Excellence in Stem Cell and Cell Therapy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Excellence Center for Stem Cell and Cell Therapy, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

ORCID-Profile: Thaninee Prasoppokakorn, Phonthep Angsuwatcharakon, Pradermchai Kongkam, Rungsun Rerknimitr

Förderung

  • The Second Century Fund (C2F), Chulalongkorn University
  • Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology annual fund, Chulalongkorn University

Zitieren

APA

Prasoppokakorn, T., Chaiteerakij, R., Buntho, A., Ingrungruanglert, P., Israsena, N., Rittitid, W., Angsuwatcharakon, P., Mekaroonkamol, P., Kongkam, P., & Rerknimitr, R. (2025). Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I–III pancreatic ductal adenocarcinoma. Endoscopy, 57(08), 901-909. https://doi.org/10.1055/a-2535-7440

Vancouver

Prasoppokakorn T, Chaiteerakij R, Buntho A, Ingrungruanglert P, Israsena N, Rittitid W, et al. Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I–III pancreatic ductal adenocarcinoma. Endoscopy. 2025;57(08):901-909. doi:10.1055/a-2535-7440

BibTeX
@article{Prasoppokakorn2025,
  author = {Prasoppokakorn, Thaninee and Chaiteerakij, Roongruedee and Buntho, Areeya and Ingrungruanglert, Praewphan and Israsena, Nipan and Rittitid, Wiriyaporn and Angsuwatcharakon, Phonthep and Mekaroonkamol, Parit and Kongkam, Pradermchai and Rerknimitr, Rungsun},
  title = {Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I–III pancreatic ductal adenocarcinoma},
  journal = {Endoscopy},
  year = {2025},
  volume = {57},
  number = {08},
  pages = {901--909},
  doi = {10.1055/a-2535-7440}
}
Kostenlos starten →